cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Bioatla Inc
5 own
4 watching
Current Price
$4
$0.21
(5.54%)
logo-bcab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
150.31M
52-Week High
52-Week High
12.15
52-Week Low
52-Week Low
2.01
Average Volume
Average Volume
0.56M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization150.31M
icon52-Week High12.15
icon52-Week Low2.01
iconAverage Volume0.56M
iconDividend Yield--
iconP/E Ratio--
What does the Bioatla Inc do?
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Read More
How much money does Bioatla Inc make?
News & Events about Bioatla Inc.
Globe Newswire
23days ago
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is...
Globe Newswire
1month ago
SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Companys management will ...
PR Newswire
2 months ago
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress Himalaya Therapeutics Announces Highlights of Recent Clinical Progress PR Newswire SAN DIEGO and SHANGHAI, Nov. 8, 2022 Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that Scott Smith, President and Sheri ...
Globe Newswire
3 months ago
SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has agreed to sell 9,745,128 ...
Frequently Asked Questions
Frequently Asked Questions
What is Bioatla Inc share price today?
plus_minus_icon
Can Indians buy Bioatla Inc shares?
plus_minus_icon
How can I buy Bioatla Inc shares from India?
plus_minus_icon
Can Fractional shares of Bioatla Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Bioatla Inc stocks?
plus_minus_icon
What is today’s traded volume of Bioatla Inc?
plus_minus_icon
What is today’s market capitalisation of Bioatla Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Bioatla Inc?
plus_minus_icon
What percentage is Bioatla Inc down from its 52-Week High?
plus_minus_icon
What percentage is Bioatla Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$4
$0.21
(5.54%)
logo-bcab
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$3.01
$0.06 (2.03 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$8.27
$0.07 (0.85 %)
FOGHORN THERAPEUTICS INC
FOGHORN THERAPEUTICS INC
$8.90
$0.30 (3.49 %)
Clene Inc
Clene Inc
$1.55
$0.02 (1.31 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
SPRUCE BIOSCIENCES INC
SPRUCE BIOSCIENCES INC
$3.01
$0.06 (2.03 %)
PMV PHARMACEUTICALS INC
PMV PHARMACEUTICALS INC
$8.27
$0.07 (0.85 %)
FOGHORN THERAPEUTICS INC
FOGHORN THERAPEUTICS INC
$8.90
$0.30 (3.49 %)
Clene Inc
Clene Inc
$1.55
$0.02 (1.31 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00